PURPOSE: To present and evaluate a new method of estimating rates of retinal ganglion cell (RGC) loss in glaucoma by combining structural and functional measurements. DESIGN: Observational cohort study. METHODS: The study included 213 eyes of 213 glaucoma patients followed up for an average of 4.5 ± 0.8 years with standard automated perimetry visual fields and optical coherence tomography. A control group of 33 eyes of 33 glaucoma patients underwent repeated tests over a short period to test the specificity of the method. An additional group of 52 eyes from 52 healthy subjects followed up for an average of 4.0 ± 0.7 years was used to estimate age-related losses of RGCs. Estimates of RGC counts were obtained from standard automated perimetry and optical coherence tomography, and a weighted average was used to obtain a final estimate of the number of RGCs for each eye. The rate of RGC loss was calculated for each eye using linear regression. Progression was defined by a statistically significant slope faster than the age-expected loss of RGCs. RESULTS: From the 213 eyes, 47 (22.1%) showed rates of RGC loss that were faster than the age-expected decline. A larger proportion of glaucomatous eyes showed progression based on rates of RGC loss rather than based on isolated parameters from standard automated perimetry (8.5%) or optical coherence tomography (14.6%; P < .01), while maintaining similar specificities in the stable group. CONCLUSIONS: The rate of RGC loss estimated from combining structure and function performed better than either isolated structural or functional measures for detecting progressive glaucomatous damage.
PURPOSE: To present and evaluate a new method of estimating rates of retinal ganglion cell (RGC) loss in glaucoma by combining structural and functional measurements. DESIGN: Observational cohort study. METHODS: The study included 213 eyes of 213 glaucomapatients followed up for an average of 4.5 ± 0.8 years with standard automated perimetry visual fields and optical coherence tomography. A control group of 33 eyes of 33 glaucomapatients underwent repeated tests over a short period to test the specificity of the method. An additional group of 52 eyes from 52 healthy subjects followed up for an average of 4.0 ± 0.7 years was used to estimate age-related losses of RGCs. Estimates of RGC counts were obtained from standard automated perimetry and optical coherence tomography, and a weighted average was used to obtain a final estimate of the number of RGCs for each eye. The rate of RGC loss was calculated for each eye using linear regression. Progression was defined by a statistically significant slope faster than the age-expected loss of RGCs. RESULTS: From the 213 eyes, 47 (22.1%) showed rates of RGC loss that were faster than the age-expected decline. A larger proportion of glaucomatous eyes showed progression based on rates of RGC loss rather than based on isolated parameters from standard automated perimetry (8.5%) or optical coherence tomography (14.6%; P < .01), while maintaining similar specificities in the stable group. CONCLUSIONS: The rate of RGC loss estimated from combining structure and function performed better than either isolated structural or functional measures for detecting progressive glaucomatous damage.
Authors: Nicholas G Strouthidis; Andrew Scott; Neena M Peter; David F Garway-Heath Journal: Invest Ophthalmol Vis Sci Date: 2006-07 Impact factor: 4.799
Authors: Paul H Artes; Neil O'Leary; Donna M Hutchison; Lisa Heckler; Glen P Sharpe; Marcelo T Nicolela; Balwantray C Chauhan Journal: Invest Ophthalmol Vis Sci Date: 2011-06-08 Impact factor: 4.799
Authors: Felipe A Medeiros; Renato Lisboa; Robert N Weinreb; Christopher A Girkin; Jeffrey M Liebmann; Linda M Zangwill Journal: Arch Ophthalmol Date: 2012-05
Authors: L A Kerrigan-Baumrind; H A Quigley; M E Pease; D F Kerrigan; R S Mitchell Journal: Invest Ophthalmol Vis Sci Date: 2000-03 Impact factor: 4.799
Authors: Felipe A Medeiros; Linda M Zangwill; Christopher Bowd; Kaweh Mansouri; Robert N Weinreb Journal: Invest Ophthalmol Vis Sci Date: 2012-10-05 Impact factor: 4.799
Authors: Carolina P B Gracitelli; Ricardo Y Abe; Andrew J Tatham; Peter N Rosen; Linda M Zangwill; Erwin R Boer; Robert N Weinreb; Felipe A Medeiros Journal: JAMA Ophthalmol Date: 2015-04 Impact factor: 7.389
Authors: Andrew J Tatham; Robert N Weinreb; Linda M Zangwill; Jeffrey M Liebmann; Christopher A Girkin; Felipe A Medeiros Journal: Invest Ophthalmol Vis Sci Date: 2013-05-07 Impact factor: 4.799
Authors: Ting Liu; Andrew J Tatham; Carolina P B Gracitelli; Linda M Zangwill; Robert N Weinreb; Felipe A Medeiros Journal: Ophthalmology Date: 2015-09-15 Impact factor: 12.079
Authors: Andrew J Tatham; Daniel Meira-Freitas; Robert N Weinreb; Amir H Marvasti; Linda M Zangwill; Felipe A Medeiros Journal: Invest Ophthalmol Vis Sci Date: 2014-01-29 Impact factor: 4.799
Authors: Felipe A Medeiros; Renato Lisboa; Robert N Weinreb; Jeffrey M Liebmann; Christopher Girkin; Linda M Zangwill Journal: Ophthalmology Date: 2012-12-12 Impact factor: 12.079